Addition of aprepitant may improve vomiting control in patients receiving oxaliplatin
the ONA take:
According to results presented at the ESMO 17th World Congress on Gastrointestinal Cancer 2015 in Barcelona, Spain, researchers have found that a three-drug combination antiemetic therapy including aprepitant or fosaprepitant significantly improved the prevention rate of nausea and vomiting in patients receiving oxaliplatin chemotherapy.
For the multicenter, open-label, phase III SENRI Trial, researchers enrolled 413 Japanese patients with colorectal cancer who were receiving oxaliplatin-based chemotherapy. Patients were randomly assigned 1:1 to receive a 5-HT3 receptor antagonist plus dexamethasone with or without aprepitant or fosaprepitant during the first course of chemotherapy. All patients received aprepitant or fosaprepitant in subsequent courses.
Results showed that significantly more patients who received an NK1 antagonist achieved no vomiting overall and no vomiting in the delayed phase than those in the control arm. Researchers also found that women had higher rates of no nausea and complete protection in the aprepitant arm than the control arm.
The standard protocol for prevention of chemotherapy-induced nausea and vomiting in patients receiving oxaliplatin-based chemotherapy is a 5-HT3 receptor antagonist plus dexamethasone.
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Some Early Breast Cancer Patients Should Have Breast Conservation Instead of Mastectomy
- BBD Regimen Efficacious as First-line Therapy for Myeloma
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Targeting AR Mutations Promising in Metastatic Prostate Cancer
- GUCS 2017: Early Immunotherapy Discontinuation in mRCC
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Myalgia-arthralgia Syndrome Associated With Taxanes in Patients with Breast Cancer
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|